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Major depressive disorder (MDD) is a complex disorder charac-
terised by a pathological distortion of affect (Jones et al., 2002). 
Antidepressants are the first line treatment for clinical MDD, but 
they are ineffective in a significant proportion of patients (Gibson 
et al., 2010). Evidence suggests that antidepressant drugs of dif-
ferent classes may evoke some convergent downstream effects at 
the messenger RNA (mRNA) level (Malki et al., 2012). Genetic 
factors can further moderate how initial upstream targets within 
each drug class relay their effects on to downstream transcrip-
tional pathways (Malki et al., 2011; Powell et al., 2013). 
Consequently, increasing the number of available compounds 
with differing upstream mechanisms, but convergent down-
stream effects, will increase our chances of effectively treating 
the disorder in patients from different genetic backgrounds.
Identifying new types of antidepressant compounds, however, 
has been slow, with most being discovered through serendipity 
(Ban, 2006). Drawing from other areas of medicine, one way to 
identify new therapeutic compounds is through drug reposition-
ing; the application of known drugs and compounds to new indi-
cations (Ashburn et al., 2004). There has been some promising 
evidence of drug repositioning in other fields of medicine using 
‘connectivity mapping’, facilitated by the use of the Library of 
Integrated Network-based Cellular Signatures (LINCS; Lamb 
et al., 2006; Vempati et al., 2014). LINCS is essentially a mRNA 
library characterising the effects of over 20,000 small-molecule 
compounds, including over 1300 FDA approved drugs, in cell 
lines (Qu and Rajpal, 2012). LINCS allows users to identify com-
pounds that elicit similar or opposite mRNA profiles to an 
experimentally-derived query mRNA signature (Qu and Rajpal, 
2012).
Promising lines of research indicate that the hippocampus, 
and more specifically, hippocampal progenitor cells, are a key tar-
get of antidepressant medications (Boldrini et al., 2009; Malberg 
et al., 2000). Indeed, recent research suggests that antidepressant 
treatment in proliferating human hippocampal progenitor cells 
primes them for a route of advanced differentiation into neurons 
(antidepressant-induced hippocampal neurogenesis), which may 
be important in mediating their therapeutic effects (Anacker 
et al., 2011). Furthermore, in the rare cases where potentially 
new antidepressant compounds have been identified (e.g. the 
melatonergic analogue, agomelatine), they too seem to enhance 
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neuroplasticity and neurogenesis in the hippocampus (Pompili 
et al., 2013).
This study attempts to tackle three main aims. First, we aim to 
investigate the effects of two antidepressants from different 
classes, a selective serotonin reuptake inhibitor (SSRI; escitalo-
pram) and a tricyclic antidepressant (nortriptyline), on mRNA 
levels in human hippocampal progenitor cells. Second, we aim to 
isolate the overlapping effects of both drugs on gene expression, 
to create an ‘antidepressant mRNA signature’. Third we aim to 
use this antidepressant mRNA signature to probe the LINCS 
database and search for other compounds that elicit similar (and 
opposite) effects on mRNA to our signature, specifically in neu-
ral progenitor cells. The identification of known antidepressant 
compounds amongst those showing similar mRNA signatures to 
our query signature would confirm we have identified function-
ally meaningful mRNA targets. Furthermore, the identification of 
other functionally relevant compounds may point towards novel 
repositioning opportunities for MDD.
Methods
The hippocampal progenitor cell line
The multipotent, human hippocampal progenitor cell line 
HPC0A07/03C (provided by ReNeuron, Surrey, UK) was used 
for all experiments, as described previously (Anacker et al., 
2011). ReNeuron’s HPC0A07/03C cells were obtained from a 
12-week old foetus and immortalised with c-mycER technology. 
In the presence of growth factors (FGF2 and EGF) and 4-OHT, 
progenitors cells proliferate indefinitely. Cells were grown 
in Dulbecco’s Modified Eagle’s Media/F12 (DMEM:F12, 
Invitrogen, Paisley, UK) supplemented with 0.03% human albu-
min (Baxter Healthcare, Compton, UK), 100 µg/mL human apo-
transferrin (Sigma, St Louis, MO, USA), 16.2 µg/mL human 
putrescine DiHCl (Sigma), 5 µg/mL human insulin (Sigma), 60 
ng/mL progesterone (Sigma), 2 mM l-glutamine (Sigma) and 40 
ng/mL sodium selenite (Sigma), 10 ng/mL human bFGF (Pepro 
Tech EC Ltd, London, UK), 20 ng/mL human EGF (Pepro Tech 
EC Ltd) and 100 nM 4-OHT (Sigma). The cell line underwent 
routine checking for mycoplasma contamination every 6 weeks. 
All cells were grown at 37°C, 5% CO2, and in a humidified 
atmosphere. Within these sets of experiments each ‘biological 
replicate’ represents a subculture of cells obtained from a differ-
ent passage.
Drug doses
The active metabolite of the SSRI escitalopram, (S)-citalopram, 
has a therapeutic window of between 50–130 ng/mL in serum, 
which corresponds to doses of between 120–313 nM in vitro. The 
active metabolite of the tricyclic antidepressant nortriptyline, 
10-hydroxynortriptyline, has a therapeutic window of between 
70–170 ng/mL, which corresponds to 233–567 nM in vitro. 
Subsequently, cells were treated with a range of doses, incorpo-
rating two therapeutically-relevant doses of each drug and a high 
drug dose group comparable to those used previously in this cell 
line (Anacker et al., 2011).
Escitalopram drug doses were achieved by dissolving escit-
alopram oxalate (Sigma) in molecular grade ethanol (Sigma) to 
form a 10 mM stock solution. Escitalopram drug doses (0 nM, 
145 nM, 290 nM and 1160 nM) were then formed by dilution of 
the stock with media, with the relative proportion of ethanol 
kept constant across all dose groups. Nortriptyline drug doses 
were achieved by dissolving nortriptyline hydrochloride 
(Sigma) in RNase free water to form a 10 mM stock solution. 
Nortriptyline drug doses (0 nM, 267 nM, 534 nM, 1068 nM) 
were then formed by dilution of the stock in media. To confirm 
that the drug doses were not toxic, we checked for any effects 
on cell death using immunohistochemistry. There was no evi-
dence of increased cell death related to any dose in either drug 
condition (see Supplementary Information).
Culture protocol
Cells were seeded for 24 h on laminin-coated 6 well plates 
(Nunclon, Roskilde, Denmark). After seeding, cells were treated 
with media containing varying doses of escitalopram oxalate or 
nortriptyline hydrochloride for 48 h. At the end of the 48-h drug 
treatment period, proliferating media was aspirated and 1 ml of 
Trireagent (Sigma) was added for RNA isolation. Our 48-h drug 
culture duration represents a midrange between the treatment 
durations of neural progenitor cells in LINCS (6, 24 and 96 h).
Transcriptomics
RNA from cell experiments was isolated using Trireagent fol-
lowing the standard protocol, with an additional ethanol precipi-
tation step to increase RNA purity. For gene expression 
experiments we utilised six biological replicates at four doses 
for each drug (total n = 24 per drug group). RNA samples were 
processed on Illumina Human HT-12 v4 Expression BeadChip 
(Illumina Inc., San Diego, CA) according to manufacturer’s pro-
tocol, see Supplementary Information.
Statistical analysis
Probes were normalised using a systematic approach incorporat-
ing the Lumi package (Du et al., 2008) and analysed using R 
(www.r-project.org). Probes were filtered to remove lowly 
detected probes and to investigate only the 7500 most variable 
probes (see Supplementary information online). We focused on 
the dose-dependent effects of each drug on gene expression. A 
linear regression was performed, where probe expression was 
selected as the dependent variable, dose as the independent vari-
able, and batch and biological replicate included as factors. The 
false discovery rate (FDR) of multiple testing corrections was 
applied to our dataset with a q-value threshold of q < 0.05.
Gene ontology analysis
To understand which biological mechanisms may be affected by 
drug dose in a hypothesis-free manner we input p-values gener-
ated from our linear regressions from each of our drug groups 
into the Gene Ontology enRIchment anaLysis and visuaLizAtion 
tool (GoriLLa; http://cbl-gorilla.cs.technion.ac.il). All probes 
nominally affected by drug dose (p ⩽ 0.05) were tested for gene 
ontology (GO) term enrichment with biological processes 
(GOTERM_BP_FAT), cellular components (GOTERM_CC_
FAT) and molecular function (GOTERM_MF_FAT). We utilised 
all probes present on the array after background correction, as 
our reference list.
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Gene co-expression networks
To visualise gene co-expression networks relating to top GO 
terms and our antidepressant mRNA signature, we used the web-
based application GeneMania (genemania.org). We input any 
nominally-significant transcripts identified in each condition into 
GeneMania, and selected the H. sapiens option, so that the tool 
would specifically draw connections between the genes in our 
experimentally-derived gene sets using human data only.
Connectivity mapping
Connectivity mapping is the use of genome-wide expression data 
from cultured human cells treated with bioactive small molecules 
to discover functional associations between drugs, genes and dis-
eases through the feature of shared gene expression changes 
(Lamb et al., 2006). The LINCS allows us to perform connectivity 
mapping and identify compounds which elicit similar downstream 
effects (positive connectivity scores) or opposite downstream 
effects (negative connectivity scores) on mRNA as our antide-
pressants. To implement connectivity mapping, we identified 
nominally-significant (p < 0.05) downregulated and upregulated 
transcripts in response to escitalopram dose or nortriptyline dose, 
or changes common to both drug doses, and input this information 
into LINCS (www.lincscloud.org). We then used the output to 
identify compounds (specifically) that elicit similar gene expres-
sion effects in neural progenitor cells (specifically). We consid-
ered any drugs as having a connectivity score of greater or equal 
to ±0.75 as potential candidates for repositioning.
Results
Escitalopram
Our results revealed no FDR-significant transcripts associated 
with escitalopram dose, but 324 were nominally (uncorrected p < 
0.05) affected by dose. Our results revealed six FDR-significant 
(q < 0.05) GO terms in cells treated with escitalopram (Figure 
1(a)); the top GO term was ‘extracellular exosome’, visualised as 
a gene co-expression network in Figure 1(b). We further input 
upregulated and downregulated transcripts associated with escit-
alopram dose into the LINCS database and identified eight com-
pounds with the strongest positive connectivity scores (similar 
effects on mRNA) and eight compounds with the strongest nega-
tive connectivity scores (opposite effects on mRNA) in neural 
progenitor cells, visualised in Figure 1(c).
Figure 1. (a) Significant GO terms activated in response to escitalopram dose. (b) The top GO term identified from our data, ‘extracellular exosome’, 
visualised as a gene co-expression network. Genes in grey represent hypothetical transcripts connecting other genes within the network, whereas 
genes in green represent those transcripts identified from our dataset. (c) Eight compounds with the strongest positive connectivity scores (similar 
effects on mRNA) and eight compounds with the strongest negative connectivity scores (opposite effects on mRNA) in neural progenitor cells.
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Nortriptyline
Our results revealed no FDR-significant transcripts associated 
with nortriptyline dose, but 458 were nominally (uncorrected p < 
0.05) affected by dose. Our results revealed nine FDR-significant 
(q < 0.05) GO terms in cells treated with nortriptyline (Figure 
2(a)); the top GO term was ‘intracellular organelle’, visualised as 
a gene co-expression network in Figure 2(b). We further input 
upregulated and downregulated transcripts associated with nor-
triptyline dose into the LINCS database and identified eight com-
pounds with the strongest positive connectivity scores (similar 
effects on mRNA) and two compounds with the strongest nega-
tive connectivity scores (opposite effects on mRNA) in neural 
progenitor cells, visualised in Figure 2(c).
Overlapping effects of antidepressants
Thirty transcripts showed common nominally-significant 
changes in both drug groups (p < 0.05); 20 out of 30 common 
transcripts were in the same direction in both drug groups (11 
upregulated, 9 downregulated; Table 1), which formed our ‘anti-
depressant mRNA signature’. The overlapping transcripts are 
also visualised as a gene co-expression network (Figure 3(a)), 
and the eight compounds with the strongest positive connectivity 
scores (similar effects on mRNA), and eight compounds with the 
strongest negative connectivity scores (opposite effects on 
mRNA) in neural progenitor cells, are visualised in Figure 3(b).
Discussion
Our results revealed that two antidepressants with differing 
upstream mechanisms activate a set of both distinct and common 
downstream molecular pathways in hippocampal progenitor 
cells. Our GO analysis revealed that escitalopram specifically 
activated gene networks relating to extracellular organelles and 
vesicles, suggesting that it is modulating pathways related to 
extracellular communication (Figure 1). However, nortriptyline 
primarily affected intracellular components and organelles sug-
gesting, conversely, that it modulates components of intracellular 
function (Figure 2).
We used expression changes associated with antidepressant 
dose to probe the LINCS database and to identify compounds 
which could be repositioned for the treatment of MDD. Neither 
antidepressant alone identified compounds with very high con-
nectivity scores; all were below ±0.75 (Figures 1 and 2), so these 
compounds should be considered more cautiously than those 
with a higher connectivity score (e.g. those identified from our 
antidepressant mRNA signature (Figure 3) discussed below). 
Figure 2. (a) Significant GO terms activated in response to nortriptyline dose. (b) The top GO term identified from our data, ‘intracellular organelle’, 
visualised as a gene co-expression network. Genes in grey represent hypothetical transcripts connecting other genes within the network, whereas 
genes in blue represent those transcripts identified from our dataset. (c) Eight compounds with the strongest positive connectivity scores (similar 
effects on mRNA) and two compounds with the strongest negative connectivity scores (opposite effects on mRNA; only two compounds identified) 
in neural progenitor cells.
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Identified compounds included those which were well-studied 
(e.g. loxapine), and relatively new compounds which may not 
have been tested in humans yet (e.g. BRD-K03354784), and so 
we will restrict our review of the suitability of compounds to 
those which are well-characterised.
In response to escitalopram dose, rutin was one of the top 
compounds with a positive connectivity score. Rutin is a citrus 
flavonoid found in a wide variety of plants such as citrus fruits 
(Davis, 1947). Numerous reports have revealed that rutin has 
antidepressant-like properties in mouse; for instance increasing 
mobility in the forced swim test (Machado et al., 2008; Nöldner 
and Schötz, 2002). Furthermore, it’s been identified as an essen-
tial antidepressant component to the medicinal herb, St John’s 
wort (Hypericum perforatum; Nöldner and Schötz, 2002). The 
compound with the highest positive connectivity score in rela-
tion to nortriptyline dose was loxapine. Loxapine is a typical 
antipsychotic medication used in the treatment of schizophrenia 
(Heel et al., 1978). Similarly to nortriptyline, loxapine has a rich 
pharmacology, and is metabolised by N-demethylation to 
amoxapine, a tetracyclic antidepressant (Cohen et al., 1982). 
Consequently, loxapine represents a compound with plausible 
repositioning potential for MDD.
Both escitalopram and nortriptyline are effective antidepres-
sants and they also show common effects on mRNA levels that 
may represent a convergent mechanism (Table 1 and Figure 3). 
Overlapping transcripts include the zinc-finger transcription fac-
tor, insulinoma-associated 1 (INSM1), a gene which has previ-
ously been found to increase the generation and expansion of 
neural progenitor cells in the neocortex (Farkas et al., 2008). 
Therefore, this gene could be important in mediating increases in 
proliferation previously reported in response to antidepressants 
(Boldrini et al., 2012). Another gene also upregulated was 
oxidation resistance 1, OXR1, which codes for a protein that spe-
cifically protects against oxidative stress (Volkert et al., 2000). 
This gene may be important in mediating protection against 
increases in reactive oxygen species hypothesised to trigger neu-
ronal atrophy in the brains of MDD patients (Michel et al., 2012). 
Consequently, both antidepressants may be activating genes 
important in progenitor proliferation and neuroprotection, which 
may be important in mediating their effects.
Despite interesting compounds being identified when consid-
ering each drug separately (described above), the main purpose 
of our study was to identify common effects of escitalopram and 
Table 1. The transcripts affected by both escitalopram and 
nortriptyline dose, which formed our ‘antidepressant mRNA signature’.
Direction of effect Gene symbol Gene name
Upregulated CASP6 Caspase-6
 CENPQ Centromere protein Q
 EAPP E2F-associated phosphoprotein
 ID2 DNA-binding protein inhibitor 
ID-2
 INSM1 Insulinoma-associated protein 1
 MGC39900 (Hypothetical protein)
 OSBPL8 Oxysterol-binding protein-
related protein 8
 OXR1 Oxidation resistance protein 1
 SCGN Secretagogin
 SNX7 Sorting Nexin 7
 SORBS2 Sorbin and SH3 domain-
containing protein 2
Downregulated CDC16 Cell division cycle protein 16 
homologue
 CSAD Cysteine sulfinic acid 
decarboxylase
 CXORF57 Chromosome X open reading 
frame 57
 HS.25892 Small nucleolar RNA host gene 
15 (non-protein coding)
 KCNJ2 Potassium voltage-gated channel 
subfamily J member 2
 LYAR Cell growth-regulating nucleolar 
protein
 MIR1974 microRNA 1974
 SLC7A5 Solute carrier family 7 member 5
 VGF VGF nerve growth factor 
inducible
Figure 3. (a) Our antidepressant mRNA signature visualised as a gene co-expression network. Genes in grey represent hypothetical transcripts 
connecting other genes within the network, whereas genes in purple represent those transcripts identified from our dataset. (b) Eight compounds 
with the strongest positive connectivity scores (similar effects on mRNA) and eight compounds with the strongest negative connectivity scores 
(opposite effects on mRNA) in neural progenitor cells.
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nortriptyline on mRNA (an antidepressant mRNA signature) and 
to identify compounds that may impinge upon these convergent 
molecular targets (Table 1 and Figure 3). Our results revealed 
compounds which evoke both reverse and similar mRNA profiles 
to our antidepressant mRNA signature (Figure 3). The drugs with 
the reverse mRNA profile represent those that hypothetically 
induce opposite downstream effects to antidepressants. The drug 
displaying the most potent reverse effects to our antidepressant 
mRNA signature (strongest negative connectivity score) was 
bafilomycin. Bafilomycin is an antibiotic which has previously 
been shown to reverse some of the adverse cardiac effects of anti-
depressants (Dennis et al., 2011). Furthermore, bafilomycin has 
been shown to prevent the re-acidification of synaptic vesicles 
in hippocampal tissue, potentially slowing the rate of neuro-
transmission across the synapse (Zhou et al., 2000). Therefore, 
functionally, bafilomycin may reverse some of the effects of anti-
depressants by slowing the release of neurotransmitters crossing 
the synapse (e.g. serotonin and noradrenaline), preventing the 
antidepressant’s initial mechanism of action, which is primarily 
to increase post-synaptic binding of serotonin and noradrenaline. 
However, this requires confirmation in further studies as the 
interactions between bafilomycin and antidepressants are not 
well understood, nor is it clear whether the effect of bafilomycin 
on synaptic vesicles is specific to the hippocampus.
Our results also revealed that the drug clomipramine had the 
highest connectivity score, suggesting it evokes similar changes 
to mRNA in neural progenitor cells as we identify in our study 
(Figure 3). Clomipramine is a tricyclic antidepressant used in the 
treatment of MDD with both serotonergic and noradrenergic 
effects (Amsterdam et al., 1997), and thus our results suggest that 
we may have identified a functionally valid set of mRNA 
changes, which can be used to identify compounds which elicit 
similar functional effects.
The drug ranked with the second highest connectivity score 
in the LINCS output was W-7 (N-(6-aminohexyl)-5-chloro-1-
naphthalenesulfonamide hydrochloride). W-7 is an intracellular 
calcium binding protein (calmodulin) antagonist (Jan et al., 2000) 
and a functionally plausible compound for drug repositioning in 
MDD. Calmodulin antagonists and inhibition of calmodulin-
dependent protein kinase II (CaMKII) disinhibit excitatory neu-
rotransmission via presynaptic metabotropic glutamate receptors, 
and enhance neurotransmitter release (Hinds et al., 2003, 
O’Connor et al., 1999). Furthermore, antidepressants and calmo-
dulin have both been shown to reverse corticosterone-induced 
gene transcription (Budziszewska et al., 2000); suggesting calm-
odulin inhibition reverses the downstream effects of stress, 
a known risk factor for MDD. Moreover, other studies have 
concluded that any interruption of the Ca2+-calmodulin- 
NOS-guanylyl cyclase subcellular signalling pathway will 
produce antidepressant-like effects (Paul, 2001).
The drug ranked with the third highest connectivity score is 
vorinostat, a histone deacetylase inhibitor, which has a similar 
mechanism of action to the mood-stabiliser sodium valproate 
(Kilgore et al., 2010). Both these medications are epigenetic 
modifiers which elicit potent effects on genome-wide gene 
expression (Covington et al., 2009). There is a considerable body 
of evidence which reveals epigenetic differences between 
MDD cases and controls (Saavedra et al., 2016). Furthermore, 
recent results from the genetic pathway analysis of an MDD 
genome-wide association study, suggest that genes regulating 
epigenetic modifications of histones might be causally related to 
MDD (The Network and Pathway Analysis Subgroup of the 
Psychiatric Genomics Consortium, 2015). Mechanistically, it 
could be that a genetic predisposition to MDD coincides with 
epigenetic modifications that result in reduced ‘transcriptional 
plasticity’, that impacts upon the propensity of hippocampal neu-
ral stem cells to differentiate (Burney et al., 2013). Indeed, hip-
pocampal neural stem cell differentiation is associated with 
widespread transcriptional reprogramming (Mody et al., 2001), 
so a reduced propensity for transcriptional change may result in a 
reduced rate of neurogenesis, and therefore may explain the 
smaller hippocampal volumes observed amongst MDD patients 
(Bremmer et al., 2000). Moreover, histone deacetylase inhibitors 
such as a vorinostat, that promote transcriptional activity across 
the genome, have previously been found to increase neurogenesis 
and neuroplasticity (Grayson et al., 2010). Thus, vorinostat may 
represent a functionally relevant compound with the potential to 
be repurposed in the treatment of MDD.
Despite the promising results, this study has a number of limi-
tations. First, we investigated the acute effects of antidepressants 
on gene expression profiles. However, studies suggest that 
chronic treatment with antidepressants may be needed in order to 
observe therapeutic or functional effects (e.g. Malberg et al., 
2000) and consequently we may be missing important gene 
expression changes linked to longer culture of progenitor cells 
with antidepressants. Thus, the short treatment duration may 
result in decreased ‘construct validity’ because it doesn’t reflect 
the same treatment duration it takes to observe clinical change, 
but because 48-h corresponds closely to the treatment duration in 
the LINCS database, the mRNA changes we identify may have 
good predictive validity in the context of drug screening (Powell 
et al., 2012).
Secondly, we cannot, using our methodology, accurately 
model the interactions of drugs in an in vivo environment where 
hormones and neurotransmitter release will moderate the effects 
of these drugs on neural stem cells. Furthermore, we can only 
provide indications as to what drugs might be promising reposi-
tioning opportunities for MDD; further functional work and, ulti-
mately, clinical trials will be needed to confirm the repositioning 
validity of identified compounds.
In conclusion, this study is the first to report the genome-wide 
effects of two antidepressants on proliferating human hippocam-
pal progenitor cells. We identify both overlapping and distinct 
effects of these drugs on mRNA levels. We isolated convergent 
effects of two antidepressants on 20 mRNA transcripts which we 
used to create an antidepressant mRNA signature to probe the 
LINCS database. Our results identified compounds which may 
reverse the effects of antidepressants (bafilomycin); compounds 
which elicit similar changes to mRNA, and are known to elicit 
the same functional effects (clomipramine); and compounds 
which show similar mRNA effects to our antidepressants with the 
potential to be repositioned as novel antidepressants (W-7, vori-
nostat). Our findings suggest that connectivity mapping and the 
use of the LINCS database may have relevance in the reposition-
ing of compounds for the treatment for MDD.
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